$パッセージ バイオ(PASG.US)$Passage Bio Announced Initial Safety And Biomarker Data From Three Cohort 1 Patients In The Ongoing Global Phase 1/2 UpliFT-D Trial Of PBFT02, An Adeno-associated Virus-delivery Gene Therapy For Frontotemporal Dementia With Granulin Mutations
Kevin Matte : seem next level around 1.6 or so ^^